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Abstract
Background: The clinicopathologic features and surgical treatment strategy of Borrmann type IV (B-4) gastric
cancer remains controversial. This meta-analysis was conducted to evaluate the clinicopathologic features of
patients with B-4 gastric cancer and to assess whether or not non-curative resection improved prognosis.
Methods: PubMed and Embase were searched for relevant articles. Statistical analysis was performed using RevMan
(version 5.2). The odds ratio (OR), risk ratio (RR), hazard ratio (HR) with 95 % confidence interval (CI), and weighted
average of median survival times were calculated as effect values.
Results: Fifteen studies were included. Compared with Borrmann type “others” (B-O), B-4 had a higher incidence of
poorly differentiated carcinoma (OR = 4.92; 95 % CI = 3.10–7.83; P < 0.01), lymph node metastases (OR = 2.13; 95 %
CI = 1.88–2.41; P < 0.01), peritoneal metastases (OR = 3.91; 95 % CI = 3.37–4.54; P < 0.01), serosal invasion (OR = 3.66;
95 % CI = 2.91–4.60; P < 0.01), and lymphatic invasion (OR = 1.39; 95 % CI = 1.02–1.91; P = 0.04). B-4 patients with
non-curative resection were associated with a worse survival rate (HR = 2.83; 95 % CI = 2.35–3.40; P < 0.01) than
patients with curative resection; however, B-4 patients with non-curative resection had a better survival rate (1-year:
RR = 0.70, 95 % CI = 0.63–0.77; P < 0.01; 2-year: RR = 0.90, 95 % CI = 0.85–0.94; P < 0.01) than patients with
non-resection.
Conclusions: Our meta-analysis indicated that B-4 patients were associated with poor tumor differentiation, lymph
node metastases, peritoneal metastases, serosal invasion, lymphatic invasion, and prognosis. Curative resection may
increase the survival rate for B-4 patients. If it is not possible to perform a curative resection, a non-curative
resection may improve the prognosis.
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Background
Gastric cancer is a common malignant disease and re-
mains the third most frequent cause of cancer deaths
worldwide [1, 2]. The classification of advanced gastric
cancer according to Borrmann’s criteria is presently ac-
cepted by many surgeons, endoscopists, and radiologists
worldwide. According to this classification, Borrmann
type IV (B-4) gastric cancer is defined as a lesion which
diffusely infiltrates to the gastric wall without ulceration
or distinct elevation [3]. The incidence of B-4 gastric
cancer is approximately 10–20 % of all gastric cancer
[4]. Several studies have analyzed the clinicopathologic
features of patients with B-4 gastric cancer, but contro-
versy still remains with respect to the incidence of hep-
atic metastases and vascular invasion [5–8]. In addition,
B-4 gastric cancer usually has a poor prognosis; the 5-
year survival rate after gastrectomy has been reported to
be approximately 30 % [8, 9]. Surgical resection is the
most suitable treatment for gastric cancer [10], but the
surgical treatment strategy for B-4 patients is controver-
sial [11–14]. Some investigations have reported that
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non-curative resection may improve the prognosis of pa-
tients with B-4 gastric cancer [13]. At the same time, it
was reported by another group that there was no statis-
tical difference between the prognosis of patients with
non-curative resection and those with non-resection
[14]. Some researchers even believe that B-4 gastric car-
cinoma is not surgically curable based on the poor out-
comes after surgery [11, 12]. The purposes of our meta-
analysis were to compare the clinicopathologic charac-
teristics (e.g., gender ratio, pathologic type, tumor me-
tastases, and invasion) between B-4 gastric cancer and
Borrmann type “others” (B-O) and to evaluate the effect-




Two investigators (Yifan Luo and Peng Gao) performed
independent searches of the electronic databases
(PubMed and Embase) from inception to January 2015.
The search strategy included the keywords “Borrmann”
and “gastric cancer” and the strategy was changed ac-
cording to different requirements for each database.
Both published and unpublished articles were included,
and no language restriction was applied. The reference
lists of all selected studies were further searched to iden-
tify other additional pertinent articles.
Inclusion and exclusion criteria
All observational and experimental studies that evalu-
ated survival of patients with B-4 gastric cancer treated
by non-curative resection were considered, and the stud-
ies that compared the clinicopathologic characteristics of
B-4 and B-O gastric carcinomas were included in the
present study. Articles without full text and data needed
that could not be acquired from the authors were ex-
cluded. In addition, letters to the editor without useful
data, case reports, and editorials were excluded. If the
same authors reported multiple investigations conducted
during the same period, we only utilized the most
complete reports in the present study.
Data extraction
Two independent researchers extracted data from
each study using a predefined table. The following
information was extracted from the included study:
author, publication time, country, sample size, clinico-
pathologic characteristics, and major end point. The
pathologic type was separated into well (tubular and
papillary adenocarcinomas)- and poorly differentiated
(poorly differentiated adenocarcinoma, mucinous car-
cinoma, and signet-ring cell carcinoma) types. If the
article did not provide the hazard ratio (HR) for over-
all survival, we used Engauge Digitizer 4.1 software to
distinguish the Kaplan–Meier curves and extract the
HRs of overall survival.
Quality assessment for included studies
The quality of each included study was independently
evaluated using the Newcastle–Ottawa Scale [15] by two
investigators, with scores ≥5 indicating high quality.
Statistical analysis
Statistical analysis was performed with RevMan (version
5.2; Cochrane Collaboration). The odds ratio (OR) and
risk ratio (RR) with 95 % confidence interval (CI) were
used for the analysis of dichotomous data, and the
weighted average of the median survival times were used
for continuous data. The HR and 95 % CI for the overall
survival were calculated with the method reported by
Tierney et al. [16]. We assessed the heterogeneity
between studies using the chi-square test, which indi-
cates the presence of significant heterogeneity at a P
value <0.05. At the same time, I2 was used to assess het-
erogeneity. An I2 > 50 % was considered to be statisti-
cally significant. For outcomes in which significant
heterogeneity was observed, a random effects model was
used; otherwise, a fixed effects meta-analysis was con-
ducted. The assessment of publication bias was evalu-
ated using the funnel plot.
Results
The included literature and methodologic quality
A flow diagram of the selection process is shown in
Fig. 1. The initial search identified 1906 studies for the
meta-analysis; 1879 studies were excluded after a review
of the titles and abstracts. After full text assessment of
the 27 eligible studies, 15 were included in this meta-
analysis according to our inclusion and exclusion
criteria. All included studies were retrospective. The
main characteristics of each included study are listed in
Table 1. The quality of the included studies was assessed
according to the Newcastle–Ottawa Scale; most of the
included studies were high quality based on the scores
(>5).
Clinicopathologic characteristics and prognosis
We demonstrated that patients with B-4 carcinoma
had significantly worse survival rates than patients
with other types of carcinomas (HR = 2.64; 95 % CI =
2.38–2.93; P < 0.01; Fig. 2a). Ten studies provided data
regarding the gender ratio. The female-to-male ratio
in the B-4 group was significantly higher than that in
the B-O group (0.82 [940/1140] vs. 0.44 [3904/8804];
pooled OR = 1.87; 95 % CI = 1.70–2.06; P < 0.01;
Fig. 2b). In the pathologic type subset, seven studies
involving 12,836 patients were divided into two prin-
cipal subgroups (well- and poorly differentiated). In
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the poorly differentiated group, the proportion of B-4
patients was significantly higher than the B-O patients
(87.98 % [1530/1739] vs. 60.39 % [6701/11,097];
pooled OR = 4.92; 95 % CI = 3.10–7.83; P < 0.01;
Fig. 2c).
In addition, ten trials [5–9, 12, 14, 17–19] showed data
on tumor metastases and invasion, which we distributed
into six subsets (lymph node metastases, hepatic metas-
tases, peritoneal metastases, lymphatic invasion, serosal
invasion, and vascular invasion). The different types of
metastases and invasion patterns resulted in different
outcomes. A higher ratio of B-4 patients with lymph
node metastases (84.38 % [1755/2080] vs. 71.29 % [9059/
12,708]; pooled OR = 2.13; 95 % CI = 1.88–2.41; P < 0.01;
Fig. 3a), peritoneal metastases (27.82 % [358/1287] vs.
9.36 % [755/8065]; pooled OR = 3.91; 95 % CI = 3.37–
4.54; P < 0.01; Fig. 3b), serosal invasion (82.31 % [1712/
2080] vs. 60.84 % [7731/12,708]; pooled OR = 3.66; 95 %
CI = 2.91–4.60; P < 0.01; Fig. 3c), and lymphatic invasion
(62.13 % [584/940] vs. 54.55 % [2983/5468]; pooled OR
= 1.39; 95 % CI = 1.02–1.91; P = 0.04; Fig. 3d) was shown
compared with B-O patients; however, there were no
statistically significant differences in vascular invasion
(pooled OR = 1.05; 95 % CI = 0.85–1.30; P = 0.62; Fig. 4a)
and hepatic metastases (3.81 % [49/1287] vs. 4.98 %
[402/8065]; pooled OR = 0.68; 95 % CI: 0.39–1.20; P =
0.19; Fig. 4b). Sensitivity analysis was performed by
omitting each individual study. When we eliminated the
Ma study [7], B-4 patients had a lower incidence of hep-
atic metastases (3.05 % [35/1148] vs. 4.98 % [364/7311];
pooled OR = 0.55; 95 % CI = 0.39–0.79; P < 0.01; Fig. 4c),
and statistically significant heterogeneity between the
remaining studies was not detected (P = 0.31, I2 = 16 %).
Efficiency of surgical treatment
A quantitative meta-analysis using the data from four
studies revealed that non-curative resection compared
with curative resection in B-4 patients was associated
with a worse survival rate (HR = 2.83; 95 % CI = 2.35–
3.40; P < 0.01; Fig. 5a). Six studies reported median sur-
vival times for B-4 patients after non-curative resection
or non-resection [13, 14, 20–23]. In these studies, 434
patients underwent non-curative resection and 304 pa-
tients underwent non-resections, such as an exploratory
laparotomy. In the non-curative resection group, the
weighted average of the median survival time was
9.8 months, whereas the weighted average of the median
survival time was 5.2 months in the other group. Five
studies provided data regarding the 1- and 2-year sur-
vival rates for B-4 patients. The 1 (RR = 0.70, 95 % CI =
0.63–0.77; P < 0.01; Fig. 5b)- and 2-year survival rates
(RR = 0.90, 95 % CI = 0.85–0.94; P < 0.01; Fig. 5c) in the
non-curative resection group had a better prognosis than
in the non-resection group. Publication bias was exam-
ined by the funnel plot. There was no evidence of publi-
cation bias among these comparisons.
Discussion
Although advances in diagnostic techniques and treat-
ment methods have improved overall treatment out-
comes for gastric cancer patients, the prognosis of B-4
gastric cancer remains poor. Patients with B-4 gastric
cancer are always in an advanced stage when diagnosed,
and some authorities attribute this finding to the special
clinicopathologic characteristics of the tumor [13]; how-
ever, the clinicopathologic characteristics and surgical
treatment strategy of B-4 patients is always in dispute.
Based on our present meta-analysis, patients with B-4
gastric cancer had a higher female-to-male ratio, more
poorly differentiated carcinomas, more lymph node
metastases, more peritoneal metastases, more serosal
invasion, more lymphatic invasion, and a poorer progno-
sis. It has been reported that patients with a poorly dif-
ferentiated pathologic type of gastric cancer are
characterized by lymph node metastases, serosal inva-
sion, peritoneal dissemination, and advanced stage [24].
Some investigators have reported that B-4 gastric cancer
predominates in females and in undifferentiated hist-
ology, invades the serosal surface, involves lymph nodes
more frequently, and has a high incidence of peritoneal
Fig. 1 Flow diagram of the studies search and selection
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dissemination [6, 9, 13, 14]. Indeed, our results are con-
sistent with these studies.
According to our findings, patients with B-4 gastric
cancer had a lower incidence of hepatic metastases,
but the difference was not statistically significant. Fur-
ther sensitivity analysis revealed that the Ma study [7]
was the primary cause of the heterogeneity. After
eliminating the Ma study [7], the incidence of hepatic
metastases was significantly lower in patients with B-
4 gastric cancer than patients with B-O, and there
was no statistically significant heterogeneity between
the remaining studies. In the hepatic metastases com-
parison, we found that patients in the Ma study [7]
had a higher serosal invasion incidence than other
studies. The high proportion of patients with an
advanced stage might be the source of the heterogen-
eity. Maehara [25] suggested that hepatic metastases
were more frequent in patients with Borrmann type 2
and 3 gastric cancer. Adacki [26] reported that most
poorly differentiated carcinomas are hypovascular and
vascular irregularity often exists. We reasoned that B-
4 gastric cancer rarely develops blood-borne metastases to
the liver might due to the large proportion of poorly dif-
ferentiated carcinomas.
The optimal treatment of patients with B-4 gastric
cancer remains a matter of debate. In 1989, Aranha [11]
concluded that B-4 gastric carcinoma is not a surgically
curable disease because of the poor post-operative sur-
vival; however, most investigators believe that the prog-
nosis is significantly worse in B-4 patients who undergo
a non-curative resection than a curative resection [6, 7,
9, 14, 18]; our results are consistent with their conclu-
sion (HR = 2.83; 95 % CI = 2.35–3.40; P < 0.01). This dif-
ference may be attributed to the advances in various
diagnostic and treatment modalities in recent decades.
In Japan, some researchers suggested that aggressive ex-
tended surgery, such as a left upper abdominal exenter-
ation plus Appleby’s method (LUAE + Apl), could
improve the survival of patients with B-4 stage III gastric
cancer [27, 28]. At present, most physicians do not rec-
ommend LUAE + Apl because it is not effective for pa-
tients with stage IV gastric cancer and may cause severe
post-operative complications. Besides, some researchers
believe that extended lymphadenectomy should be
Table 1 Characteristics of included studies



























1992 Japan 194/919 17.4 NA NA NA NA NA NA NA NA 6
Kitamura
[14]
1995 Japan 102/563 15.3 50 11.1 NA NA 13 6.2 NA NA 5
Tanigawa
[17]
1998 Japan 33/169 16.3 NA NA NA NA NA NA NA NA 6
Otsuji [12] 1999 Japan 150/698 17.7 NA NA NA NA NA NA NA NA 5
Yokota [19] 1999 Japan 88/309 22.2 NA NA NA NA NA NA NA NA 6
Kodera [22] 2001 Japan 70/0 NA 31 9.7 35.48 % 12.90 % 11 8 27.27 % 9.09 % 6
Chen [5] 2002 China 103/604 14.6 NA NA NA NA NA NA NA NA 5
Kim [18] 2002 Korea 199/
1607
11 NA NA NA NA NA NA NA NA 5
Yook [13] 2005 Korea 370/
3693





8.3 254 9 37.80 % 14.57 % 116 4.33 7.76 % 0.86 % 5
An [8] 2008 Korea 555/
3636
13.2 NA NA NA NA NA NA NA NA 4
Li [9] 2009 China 517/
3449
13 NA NA NA NA NA NA NA NA 5
Accetta
[20]
2011 Brazil 123/836 12.8 16 10 NA 13.00 % 55 3 NA 0 5
Gao [21] 2011 China 118/0 NA 32 11.6 40.60 % 6.20 % 19 6.1 15.80 % 0 5
Ma [7] 2012 China 139/754 15.6 NA NA NA NA NA NA NA NA 7
NOS Newcastle–Ottawa Scale, B-4 Borrmann type IV, B-O Borrmann type “others”, NA not applicable
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performed if patient’s clinical condition allowed, because
it may allow a better assessment of nodal stations and
decrease the chance of stage worsening [20].
Moreover, there is some controversy regarding the role
of non-curative resection for survival. Kodera [22] re-
ported that such an aggressive surgical attitude is likely
to prove futile for B-4 gastric cancer patients. Yook [13]
demonstrated that non-curative resection may lengthen
the survival time in B-4 patients with peritoneal dissem-
ination. We found that the 1-year survival rate in the
non-curative resection group had a significantly better
prognosis than in the non-resection group (RR = 0.70,
95 % CI = 0.63–0.77; P < 0.01). Although the difference
in the 2-year survival rate between the two groups was
smaller (RR = 0.90, 95 % CI = 0.85–0.94; P < 0.01), statis-
tical differences still existed. Because the patients with-
out curative resection do not usually survive 2 years, we
could not compare the 3- or 5-year survival between the
non-resection and non-curative resection groups. Based
on our research, the weighted average of the median sur-
vival time in the non-curative resection group
(9.8 months) was longer than in the non-resection group
Fig. 2 Forest plot displaying the results of meta-analysis. a Hazard ratio for overall survival of patients with B-4 or B-O. b Odds ratio for gender
ratio. c Odds ratio for pathologic type (B-4 Borrmann type IV, B-O Borrmann type “others”, PD poorly differentiated carcinoma)
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Fig. 3 Forest plot displaying the results of meta-analysis. a Odds ratio for lymph node metastases. b Odds ratio for peritoneal metastases. c Odds
ratio for serosal invasion. d Odds ratio for lymphatic invasion (B-4 Borrmann type IV, B-O Borrmann type “others”, LM lymph node metastases, PM
peritoneal metastases, SI serosal invasion, LI lymphatic invasion)
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(5.2 months). This result showed that patients with non-
curative resection might have a beneficial survival com-
pared to patients with non-resection, and non-curative
resection may improve the quality of life of the patients
through relief of symptoms, such as bleeding, strictures,
pain, or malnutrition [23]. It has also been suggested
that it is not necessary to obtain a negative surgical mar-
gin at the time of a non-curative resection because pa-
tients with negative and positive resection margins of
the gastrectomy with peritoneal disseminations had
similar survival rates [13]; some researchers believe that
for B-4 patients with peritoneal disseminations but with-
out passage disturbance, non-curative resection should
be replaced by chemotherapy [23]. However, more re-
search into this issue is warranted before a final conclu-
sion can be drawn. A randomized controlled trial (RCT)
is designed to evaluate the superiority of non-curative
resection followed by chemotherapy to chemotherapy
alone in terms of overall survival [29]. We look forward
to the results of this clinical trial.
Certainly, there were several limitations in our study.
First, none of the studies we used in this meta-analysis
were RCT studies. Patients were not randomized to non-
curative resection or non-resection groups. As a result,
we could not ignore the possibility that the non-curative
resection group had a better prognosis than the non-
resection group due to the difference in patient status;
however, in the absence of RCT studies, performing a
meta-analysis of retrospective studies, which represents
the best evidence available, is necessary and helpful. Sec-
ond, the sample sizes of some included studies were
relatively small and may have weakened the statistical
Fig. 4 Forest plot displaying the results of meta-analysis. a Odds ratio for vascular invasion. b Odds ratio for hepatic metastases. c Sensitivity
analysis of odds ratio for hepatic metastases (B-4 Borrmann type IV, B-O Borrmann type “others”, VI vascular invasion, HM hepatic metastases)
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power. Third, with the exception of one study from
Brazil, most of our included studies were from Asian
countries; thus, the conclusions might not apply to cases
outside of Asia, and the results should be further con-
firmed by studies involving more countries.
Conclusions
In conclusion, our meta-analysis demonstrated that B-4
gastric cancer patients had a higher female-to-male ratio,
more poorly differentiated carcinomas, more lymph
node metastases, more peritoneal metastases, more se-
rosal invasion, more lymphatic invasion, and a poorer
prognosis. Curative resection of B-4 gastric cancer may
increase the survival rate if detected at an early stage.
Even if it is not possible to perform curative resection,
the effort required to perform non-curative resection
may improve the prognosis of patients with B-4 gastric
cancer. In the future, all of our results need further con-
firmation based on well-designed multi-center RCTs
from more countries.
Abbreviations
B-4: Borrmann type IV; B-O: Borrmann type “others”; CI: confidence interval;
HR: hazard ratio; LUAE + Apl: left upper abdominal exenteration plus
Appleby’s method; OR: odds ratio; RCT: randomized controlled trial; RR: risk
ratio.
Competing interests
The authors declare that they have no competing interests.
Authors’ contributions
WZN and LYF participated in the design of the study. LYF, GP, LY, and MB
performed the research and extracted the data. LYF, GP, SJX, SYX, HXZ, and
ZJH were involved in drafting the manuscript. LYF and GP contributed
equally to this work. All authors read and approved the final manuscript.
Acknowledgements
We thank the department of Surgical Oncology of First Hospital of China
Medical University and the College of China Medical University for their
technical assistance in this analysis.
Funding
This work was supported by Natural Science Foundation of Liaoning Province
(No. 2014029201), Program of Education Department of Liaoning Province
(L2014307), and Clinical Capability Construction Project for Liaoning Provincial
Hospitals (LNCCC-A01-2014). The funders had no role in the study design, data
collection and analysis, decision to publish, or preparation of the manuscript.
Fig. 5 Forest plot displaying the results of meta-analysis. a: Hazard ratio for overall survival of patients with Borrmann type IV gastric cancer
received non-curative resection or curative resection. b: Risk ratio for 1-year survival of patients with Borrmann type IV gastric cancer received
non-curative resection or non-resection. c: Risk ratio for 2-year survival of patients with Borrmann type IV gastric cancer received non-curative
resection or non-resection
Luo et al. World Journal of Surgical Oncology  (2016) 14:49 Page 8 of 9
Received: 21 September 2015 Accepted: 17 February 2016
References
1. Torre LA, Bray F, Siegel RL, Ferlay J, Lortet-Tieulent J, Jemal A. Global cancer
statistics, 2012. CA Cancer J Clin. 2015;65:87–108. doi:10.3322/caac.21262.
2. Bertuccio P, Chatenoud L, Levi F, Praud D, Ferlay J, Neqri E, et al. Recent
patterns in gastric cancer: a global overview. Int J Cancer. 2009;125:666–73.
doi:10.1002/ijc.24290.
3. Borrmann R. Geschwulste des Magens und des Duodenums. In: Henke F,
Lubarsch O, editors. Handbuch Spez Pathol Anat und Histo. Berlin: Springer
Verlag; 1926. p. 812–1054. doi:10.1007/978-3-7091-5436-6_7.
4. Bollschweiler E, Boettcher K, Hoelscher AH, Sasako M, Kinoshita T, Maruyama
K, et al. Is the prognosis for Japanese and German patients with gastric
cancer really different? Cancer. 1993;71:2918–25. doi:10.1002/1097-
0142(19930515)71. 10 < 2918::AID-CNCR2820711006 >3.0.CO;2-V.
5. Chen CY, Wu CW, Lo SS, Hsieh MC, Lui WY, Shen KH. Peritoneal
carcinomatosis and lymph node metastasis are prognostic indicators in
patients with Borrmann type IV gastric carcinoma. Hepatogastroenterology.
2002;49:874–7.
6. Maehara Y, Moriguchi S, Orita H, Kakeji Y, Haraguchi M, Korenaga D, et al.
Lower survival rate for patients with carcinoma of the stomach of Borrmann
type IV after gastric resection. Surg Gynecol Obstet. 1992;175:13–6.
7. Ma JP, Chen JH, Cai SR, Chen CQ, Yang DJ, Wu H, et al. Clinicopathologic
features and prognostic analyses of Borrmann type IV gastric cancer [In
Chinese]. Zhonghua Yi Xue Za Zhi. 2012;92:2534–7. doi:10.3760/cma.j.issn.
0376-2491.2012.36.005.
8. An JY, Kang TH, Choi MG, Noh JH, Sohn TS, Kim S. Borrmann type IV: an
independent prognostic factor for survival in gastric cancer. J Gastrointest
Surg. 2008;12:1364–9. doi:10.1007/s11605-008-0516-9.
9. Li C, Oh SJ, Kim S, Hyung WJ, Yan M, Zhu ZG, et al. Macroscopic Borrmann
type as a simple prognostic indicator in patients with advanced gastric
cancer. Oncology. 2009;77:197–204. doi:10.1159/000236018.
10. Okines A, Verheij M, Allum W, Cunningham D, Cervantes A. Gastric cancer:
ESMO clinical practice guidelines for diagnosis, treatment and follow-up.
Ann Oncol. 2010;21:50–4. doi:10.1093/annonc/mdq164.
11. Aranha G, Georgen R. Gastric linitis plastica is not a surgical disease. Surgery.
1989;106:758–62.
12. Otsuji E, Yamaguchi T, Sawai K, Sakakura C, Okamoto K, Takahashi T.
Regional lymph node metastasis as a predictor of peritoneal carcinomatosis
in patients with Borrmann type IV gastric carcinoma. Am J Gastroenterol.
1999;94:434–7. doi:10.1111/j.1572-0241.1999.873_b.x.
13. Yook JH, Oh ST, Kim BS. Clinicopathological analysis of Borrmann type IV
gastric cancer. Cancer Res Treat. 2005;37:87–91. doi:10.4143/crt.2005.37.2.87.
14. Kitamura K, Beppu R, Anai H, Ikejiri K, Yakabe S, Sugimachi K, et al.
Clinicopathologic study of patients with Borrmann type IV gastric
carcinoma. J Surg Oncol. 1995;58:112–7. doi:10.1002/jso.2930580208.
15. Stang A. Critical evaluation of the Newcastle-Ottawa scale for the
assessment of the quality of nonrandomized studies in meta-analyses. Eur J
Epidemiol. 2010;25:603–5. doi:10.1007/s10654-010-9491-z.
16. Tierney JF, Stewart LA, Ghersi D, Burdett S, Sydes MR. Practical methods for
incorporating summary time-to-event data into meta-analysis. Trials. 2007;8:
16. doi:10.1186/1745-6215-8-16.
17. Tanigawa N, Amaya H, Matsumura M, Lu C, Iki M. Association between
tumor angiogenesis and Borrmann type 4 carcinomas of the stomach.
Oncology. 1998;55:461–7. doi:10.1159/000011896.
18. Kim DY, Kim HR, Kim YJ, Kim SK. Clinicopathological features of patients
with Borrmann type IV gastric carcinoma. ANZ J Surg. 2002;72:739–42. doi:
10.1046/j.1445-2197.2002.02523.x.
19. Yokota T, Teshima S, Saito T, Kikuchi S, Kunii Y, Yamauchi H. Borrmann’s
type IV gastric cancer: clinicopathologic analysis. Can J Surg. 1999;42:371–6.
20. Accetta AC, Manso JE, Mello EL, Paiva RK, Castro Ldos S, Accetta P. Type IV
Borrmann gastric adenocarcinoma: analysis of curative resection results. Rev
Col Bras Cir. 2011;38:237–44.
21. Gao HY, Zhang M, Wei YZ, Xue YW. The biological behavior characteristics
and prognosis of Borrmann type IV gastric cancer [in Chinese]. Chinese
Journal of General Surgery. 2011;26:65–6. doi:10.3760/cma.j.issn.1007-631X.
2011.01.022.
22. Kodera Y, Yamamura Y, Ito S, Kanemitsu Y, Shimizu Y, Hirai T, et al. Is
Borrmann type IV gastric carcinoma a surgical disease? An old problem
revisited with reference to the result of peritoneal washing cytology. J Surg
Oncol. 2001;78:175–81. doi:10.1002/jso.1144.
23. Nashimoto A, Yabusaki H, Nakagawa S. Treatment strategy for the type IV
gastric cancer—from the standpoint of the surgery [in Japanese]. Jpn J
Cancer Chemother. 2007;34:983–7.
24. Adachi Y, Yasuda K, Inomata M, Sato K, Shiraishi N, Kitano S. Pathology and
prognosis of gastric carcinoma: well versus poorly differentiated type.
Cancer. 2000;89:1418–24. doi:10.1002/1097-0142(20001001)89. 7<1418::AID-
CNCR2>3.0.CO; 2-A.
25. Maehara Y, Moriguchi S, Kakeji Y, Kohnoe S, Korenaga D, Haraguchi M, et al.
Pertinent risk factors and gastric carcinoma with synchronous peritoneal
dissemination or liver metastasis. Surgery. 1991;110:820–3.
26. Adachi Y, Mori M, Enjoji M, Sugimachi K. Microvascular architecture of early
gastric carcinoma: microvascular-histopathologic correlates. Cancer. 1993;72:
32–6. doi:10.1002/1097-0142(19930701)72:1<32::AID-CNCR2820720108>3.0.
CO;2-6.
27. Furukawa H, Hiratsuka M, Iwanaga T. A rational technique for surgical
operation on Borrmann type 4 gastric carcinoma: left upper abdominal
evisceration plus Appleby’s method. Br J Surg. 1988;75:116–9. doi:10.1002/
bjs.1800750209.
28. Furukawa H, Hiratsuka M, Iwanaga T, Imaoka S, Ishikawa O, Kabuto T, et al.
Extended surgery—left upper abdominal exenteration plus Appleby’s
method—for type 4 gastric carcinoma. Ann Surg Oncol. 1997;4:209–14. doi:
10.1007/BF02306612.
29. Fujitani K, Yang HK, Kurokawa Y, Park Do J, Tsujinaka T, Park BJ, et al.
Randomized controlled trial comparing gastrectomy plus chemotherapy
with chemotherapy alone in advanced gastric cancer with a single non-
curable factor: Japan Clinical Oncology Group Study JCOG 0705 and Korea
Gastric Cancer Association Study KGCA01. Jpn J Clin Oncol. 2008;38:504–6.
doi:10.1093/jjco/hyn058.
•  We accept pre-submission inquiries 
•  Our selector tool helps you to find the most relevant journal
•  We provide round the clock customer support 
•  Convenient online submission
•  Thorough peer review
•  Inclusion in PubMed and all major indexing services 
•  Maximum visibility for your research
Submit your manuscript at
www.biomedcentral.com/submit
Submit your next manuscript to BioMed Central 
and we will help you at every step:
Luo et al. World Journal of Surgical Oncology  (2016) 14:49 Page 9 of 9
